Edition:
United Kingdom

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

0.71USD
15 Dec 2017
Change (% chg)

$0.04 (+6.12%)
Prev Close
$0.67
Open
$0.68
Day's High
$0.78
Day's Low
$0.68
Volume
393,318
Avg. Vol
138,305
52-wk High
$3.53
52-wk Low
$0.56

Chart for

About

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved... (more)

Overall

Beta: --
Market Cap(Mil.): $33.27
Shares Outstanding(Mil.): 39.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Zosano Pharma Says Board To Reduce Size To Five

* ZOSANO PHARMA SAYS BOARD OF DIRECTORS ADOPTED A RESOLUTION TO REDUCE SIZE OF BOARD TO FIVE DIRECTORS - SEC FILING Source: (http://bit.ly/2j7YwDM) Further company coverage:

15 Dec 2017

BRIEF-Zosano pharma Q3 loss per share $0.20

* Zosano pharma reports third quarter 2017 financial results and operational update

09 Nov 2017

BRIEF-Zosano Pharma announces initiation of long-term safety study for M207

* Zosano Pharma announces initiation of long-term safety study for M207 as an acute treatment of migraine Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Zosano enters into common stock purchase agreement with Lincoln Park Capital

* Zosano enters into common stock purchase agreement with Lincoln Park Capital Source text for Eikon: Further company coverage:

20 Oct 2017

BRIEF-Zosano appoints Kenneth Greathouse to board of directors

* Zosano appoints Kenneth Greathouse to board of directors Source text for Eikon: Further company coverage:

04 Oct 2017

BRIEF-Zosano provides patent application update

* Zosano Pharma Corp - Received official written notification of an office action from U.S. patent and trademark office

26 Sep 2017

BRIEF-Zosano Pharma Q2 loss per share $0.17

* Zosano Pharma reports second quarter 2017 financial results and operational update

10 Aug 2017

BRIEF-Zosano Pharma announces outcome of end of phase 2 meetings with FDA

* Zosano Pharma announces outcome of end of phase 2 meetings with FDA

26 Jun 2017

Earnings vs. Estimates